These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3121868)

  • 21. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 22. Flutamide approved for prostate cancer.
    Oncology (Williston Park); 1989 Mar; 3(3):135. PubMed ID: 2518157
    [No Abstract]   [Full Text] [Related]  

  • 23. [Excretion of urinary hydroxyproline in urinary tract diseases].
    Guarino A; Comar OB; Taccone W; Cicalese V
    Arch Sci Med (Torino); 1979; 136(2):249-54. PubMed ID: 92978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma.
    Bishop MC; Fellows GJ
    Br J Urol; 1977; 49(7):711-6. PubMed ID: 597712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of urinary hydroxyproline elimination in the detection of bone metastases secondary to prostatic carcinoma].
    de la Peña J; Cárcamo P; Martínez ME; Martínez-Piñeiro JA
    Actas Urol Esp; 1983; 7(3):199-204. PubMed ID: 6624563
    [No Abstract]   [Full Text] [Related]  

  • 26. Pathologic changes associated with androgen deprivation therapy for prostate cancer.
    Murphy WM; Soloway MS; Barrows GH
    Cancer; 1991 Aug; 68(4):821-8. PubMed ID: 1906775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of calcitonin and hexestrol on urinary excretion of hydroxyproline in a patient with prostatic cancer and bone metastases.
    Matsushita Y; Hasegawa K; Sugimura R; Otomo S; Morii H
    Endocrinol Jpn; 1974 Apr; 21(2):109-13. PubMed ID: 4408206
    [No Abstract]   [Full Text] [Related]  

  • 28. Luteinizing hormone releasing hormone agonists: the US experience.
    Nabors W; Crawford ED
    J Int Med Res; 1990; 18 Suppl 1():31-4. PubMed ID: 2108884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of flutamide in hormone-refractory metastatic prostate cancer.
    McLeod DG; Benson RC; Eisenberger MA; Crawford ED; Blumenstein BA; Spicer D; Spaulding JT
    Cancer; 1993 Dec; 72(12 Suppl):3870-3. PubMed ID: 8252506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
    Trachtenberg J
    J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 32. Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide).
    Koutsilieris M; Dupont A; Gomez J; Cusan L; Suburu R; Diamond P; Labrie F
    Anticancer Res; 1994; 14(2B):627-34. PubMed ID: 8010719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
    Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer (II): Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and tumor markers in blood and urine].
    Nemoto S; Rinsho K
    Nihon Hinyokika Gakkai Zasshi; 1984 Jan; 75(1):53-8. PubMed ID: 6539837
    [No Abstract]   [Full Text] [Related]  

  • 37. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
    Niell HB; Palmieri GM; Neely CL; McDonald MW
    Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary hydroxyproline excretion in patients with cancer.
    Guzzo CE; Pachas WN; Pinals RS; Krant MJ
    Cancer; 1969 Aug; 24(2):382-7. PubMed ID: 5796782
    [No Abstract]   [Full Text] [Related]  

  • 39. Leuprolide plus flutamide: combined androgen blockade in the treatment of advanced prostate cancer.
    Chodoff L
    Mt Sinai J Med; 1990 May; 57(3):171-3. PubMed ID: 2115128
    [No Abstract]   [Full Text] [Related]  

  • 40. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D; Adalar N; Güvençli S; Simşek F
    Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.